Introduction and rationale {#sec0005}
==========================

Stroke is the leading cause of adult disability worldwide.[@bib0160] Amongst the limitations in daily living activities, the ability to walk is reported by patients as the most important activity to recover after a stroke.[@bib0165], [@bib0170] In addition, higher walking ability is related to greater independence and social participation; both performance and capacity of walking have been shown to predict participation.[@bib0175] Thus, recovery of walking after stroke is one of the most important goals in neurological rehabilitation.[@bib0180]

Assistive devices, such as canes and crutches, are usually prescribed for individuals after stroke with the purpose of improving walking and increasing safety.[@bib0185] Previous studies have examined the effects of assistive devices on walking parameters in individuals with stroke.[@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210] The results suggested that assistive devices increase step length[@bib0195] and comfortable and maximum walking speeds,[@bib0190], [@bib0210] decrease cadence,[@bib0190] and improve walking symmetry.[@bib0200] No significant changes in maximum joint angles[@bib0190] or trunk movements[@bib0205] have been found. A narrative review[@bib0215] summarized the effects of using a cane on walking in people with stroke. Although 19 experimental studies were included, methodological shortcomings, such as the absence of randomized trials and the predominance of cross-sectional studies with small samples (*n* \< 20 participants), prevent the drawing of convincing conclusions regarding the effects of using a cane on walking. In addition, many of these studies included participants, who had been habitually using a cane, so that the magnitude of the benefits may have been overestimated.

More recently, Nascimento et al.[@bib0220] conducted an experimental study to investigate the effects of the provision of a single-point cane in a heterogeneous group of community-dwelling people with stroke, who were naïve to the use of assistive devices for walking. Overall, the provision of a cane did not improve walking speed or cadence, and produced a small benefit in step length. However, sub-group analyses demonstrated clinically meaningful increases in walking speed, step length, and cadence for individuals classified as slow and intermediate walkers, i.e., walking speeds ≤0.8 m/s. These results reinforce the need to target interventions to those who will most benefit and avoid the risk of not implementing worthwhile interventions.[@bib0220], [@bib0225]

It has also been suggested that the provision of a cane can improve walking confidence.[@bib0230] Even though walking ability is an important predictor of participation in people with stroke,[@bib0175] there were not found any studies on the benefits of using a cane on community participation. The most logical time to prescribe walking aids to people with stroke is after their independent walking has stabilized, since, at this stage, there would be no likelihood of interfering with the development of independent walking. A randomized trial to investigate the effects of the provision of a cane to ambulatory individuals with chronic stroke, naïve to the use of assistive devices, on walking and participation after stroke is, therefore, warranted. The specific research questions are:1.Does the provision of a cane improve walking (speed, step length, cadence, capacity, confidence) in ambulatory individuals with chronic stroke?2.Are the benefits carried over to participation?

Methods {#sec0010}
=======

Design {#sec0015}
------

A prospective, randomized controlled trial with concealed allocation, blinded measurers, and intention-to-treat analysis will be carried-out ([Fig. 1](#fig0005){ref-type="fig"}). Community-dwelling people with chronic stroke will be recruited from the general community, by means of advertisements and by screening public rehabilitation services and lists of previous research projects. Participants will be randomly allocated into either experimental group (i.e., provision of a cane) or control group (i.e., placebo intervention). Outcome measures will be collected by trained researchers at baseline (Week 0), at the end of the intervention (Week 4), and one month beyond the intervention (Week 8). Analyses of inclusion criteria, getting the informed consent, data collection, and statistical analyses will be carried-out by researchers, who will be blinded to group allocation. All the participants will be evaluated and receive all the information regarding the interventions in a research laboratory. The study obtained ethical approval from the Research Ethical Committee (CAAE: 65765817.3.0000.5149) of the *Universidade Federal de Minas Gerais*, Belo Horizonte, Minas Gerais, Brazil. The trial was prospectively registered at the [www.ClinicalTrials.gov](http://www.clinicaltrials.gov/){#intr0015} ([NCT03150979](ctgov:NCT03150979){#intr0020}).Figure 1Design of the trial.

Participants and therapists -- inclusion and exclusion criteria {#sec0020}
---------------------------------------------------------------

Participants will be individuals with stroke, who will be eligible, if they:•are \>20 years of age;•are between 6 months and 5 years after their last episode of stroke;•have hemiparesis, i.e., weakness of the knee flexor/extensor and/or hip flexor muscles[@bib0235];•are able to walk at least 14 m, independently;•walk at speeds ≤ 0.8 m/s;•are naïve to the use of assistive devices for walking; and•provide written consent.

They will be excluded, if they have:•cognitive deficits, which will be screened by the Mini-Mental State Examination. The cut-off scores are 26 for people with high levels of education, 18 for people with elementary and middle levels, and 13 for illiterate people[@bib0240];•other non-stroke related conditions.

Therapists, who will deliver the intervention, will be eligible if they have more than two years of clinical experience in the area of neurological rehabilitation.

Randomization {#sec0025}
-------------

Randomization will be computer-generated, by a researcher not involved in participant recruitment, and stratified according to the baseline walking speeds: slow (\<0.4 m/s) and intermediate (0.4--0.8 m/s) walkers, to ensure an even spread between the groups. The allocation of the participants will be concealed in sequentially numbered, and sealed in opaque envelopes, prepared prior to the study by a research assistant, who will not be involved in the study. After the baseline measures have been collected, participants will be randomly assigned to the experimental or control groups by the treating therapist, after revealing the content of the sealed opaque envelopes. All outcomes will be measured by blinded assessors. All enrolled participants will receive a code, in order to protect confidentiality before, during, and after the trial.

Intervention {#sec0030}
------------

The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the height of the ulnar process of the participants' non-paretic upper limb, while they are standing with their elbows in extension.[@bib0190] A physical therapist will provide instructions and training on how to walk with the cane. Individuals will be instructed to hold the cane with their non-paretic hand, to allow for the maintenance of reciprocal walking patterns, taking the first step by moving forward the paretic limb and cane together.[@bib0190] Participants will practice for about 15 min or until they feel comfortable to walk with the cane. At that time, they will receive the cane and instructions to use it for walking, according to the following sentence: "Feel free to use the cane anytime you need to walk". Once a week, the participants will be contacted by a physical therapist, to ensure that they are comfortable in using the cane and clarify any problems. In the middle of the intervention period (Week 2), a home visit is planned and the treating therapist will make adjustments on the cane and solve any doubts, if necessary.

The control group will receive a placebo intervention. A physical therapist will provide instructions and training on how to perform self-stretching exercises of the lower limb muscles. Participants will receive a booklet, containing written and visual descriptions of the stretching exercises and recommendations for daily practice. A recommendation for not using assistive devices when walking will be provided, as follows: "avoid using assistive devices for walking, such as canes, stickers, and walkers; however, if you decide to use them, write it down". The control group will also receive the phone calls/home visits and undertake the same testing protocol as the experimental group. This will avoid bias related to the amount of attention. If training proves to be effective, the control group will be offered the intervention.

The intervention will be undertaken in the participant\'s home, which will reduce costs and may result in good compliance.[@bib0245], [@bib0250] On the other hand, this means that the training is not directly supervised. To record compliance, participants will receive the Life-Space Diary,[@bib0255] in which the information regarding the use and non-use of the cane for walking in various environments will be registered. The Life-Space diary is a sheet of A4 paper, with five concentric zones listed in the first column (bedroom, rest of the dwelling, grounds surrounding the dwelling, the "block" in which the dwelling is located, and the area across the traffic-bearing street), and with 31 other columns each representing a day in the month. The diary is ruled and divided into boxes. Participants will be instructed to place a tick in each box every evening, representing the zones to where they had moved during that day and to indicate whether they used or not a cane for walking. Additional rows are provided to indicate other places where the participant might go.[@bib0255] When required, a caregiver will be instructed to help them. To encourage the participants to comply with the protocol, both groups will be asked to sign a symbolic contract of commitment to the proposed protocol.[@bib0250]

Primary outcome {#sec0035}
---------------

The primary outcome is comfortable walking speed, measured by the 10-m Walk Test, and reported in m/s. The participants will be instructed to walk at their "comfortable speed" along a 14-m hallway, and the time to cover the central 10 m will be recorded with a digital stopwatch and converted to speed.[@bib0260] Walking speed will be measured with and without the cane.

Secondary outcomes {#sec0040}
------------------

Secondary outcomes are walking step length, walking cadence, walking capacity, walking confidence, and participation.

Walking step length and cadence will be measured using the 10-m Walk Test. Step length will be calculated by dividing the covered distance, i.e., 10 m, by the number of steps to cover the distance, and reported in meters. Walking cadence will be calculated by dividing the number of steps by the time to cover the distance, i.e., 10 m, and reported in steps/min.[@bib0225]

Walking capacity will be measured using the 6-min Walk Test, and reported as the covered distance (m). By using a standardized protocol,[@bib0265] participants will be instructed to cover the maximum distance, as possible, taking rests as needed.

Walking confidence will be measured using the Modified Gait Efficacy Scale, and reported as scores ranging from 10 to 100. This scale is a 10-item measure that addresses the perception of the level of confidence in walking during challenging circumstances. The items include walking on a level surface and on grass, stepping over an obstacle, stepping up and down a curb, ascending and descending stairs (with and without a handrail), and walking over a long distance.[@bib0270] The items are individually scored on a 10-point Likert scale, with 1 indicating "no confidence", and 10 indicating "complete confidence".[@bib0270]

Participation will be measured using the Brazilian version of the Stroke Impact Scale 3.0. The scale covers eight domains and the participation domain will be used. Scores range from zero to 100 and higher scores indicate higher levels of participation.[@bib0275]

Data monitoring body {#sec0045}
--------------------

An independent researcher, who will be blind to the group allocations, will monitor any adverse effects and perform database management and statistical analyses. The treating therapists will be responsible for monitoring of doses and compliance.

Sample size estimation {#sec0050}
----------------------

Fifty participants will be recruited, with walking speed as the primary outcome. The sample size has been calculated, to reliably detect a between-group difference of 0.20 m/s in walking speed, with 80% power, at a two-tailed significance level of 0.05. In a previous trial[@bib0220] with a similar sample of community-dwelling people after stroke, the mean walking speed of the slow and intermediate walkers was 0.46 m/s (SD 0.24 m/s), using the same measurement procedure as the present protocol. The least number of participants needed to detect a 0.20 m/s difference between two independent groups is 23 per group, i.e., 46 participants in total. Based on the assumption that about 10% of participants may dropout during the study, a target of 50 participants in total has been set.

Statistical analyses {#sec0055}
--------------------

Data collection will yield six variables, which reflect walking and participation: walking speed (m/s), walking step length (m), walking cadence (steps/min), walking capacity (m), walking confidence (Gait Efficacy Scale score), and participation (Stroke Impact Scale 3.0 participation sub-scale score). There are two factors (group\*time), with repeated measures on the time factor. Two-way analyses of variance with repeated measures at all time-points for all outcomes will be reported to evaluate the statistical significance of the between-group differences. The mean between-group differences, along with 95% confidence intervals, will be reported for all outcomes. The effect of the intervention will be calculated based on intention-to-treat analyses.

Study organization and funding {#sec0060}
------------------------------

This trial will be conducted according to relevant ethical frameworks and has received approval from the institutional ethical review board. It is funded by the following Brazilian national funding agencies: *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (CNPq) and *Fundação de Amparo à Pesquisa de Minas Gerais* (FAPEMIG).

Discussion {#sec0065}
==========

This trial will examine the efficacy of the provision of a cane on walking and participation in individuals with chronic stroke. Although previous studies[@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210], [@bib0215], [@bib0220] have investigated the effect of using a cane for walking after stroke, methodological shortcomings (e.g., design and small sample sizes) and differences regarding sample characteristics (e.g., time since stroke) and characteristics of interventions (e.g., time to implement intervention, type of cane) prevent drawing clear conclusions, which could help clinicians in their decision-making process. In addition, no previous trials have investigated whether benefits in walking carry over to participation. In response to this challenge, a single-blind randomized trial will be conducted. High internal validity is expected, due to randomization, concealed allocation, blinding of assessors, intention-to-treat analysis,[@bib0280] and appropriate sample size.

The most logical time to prescribe walking aids to people with stroke is after their independent walking has stabilized, since, at this stage, there would be no likelihood of interfering with the development of independent walking. In addition, the question as to whether a cane can improve walking is best answered during the chronic stages, so that it is not confounded by recovery during active rehabilitation at the acute stages.[@bib0220] Therefore, this trial will only include participants at the chronic stages after stroke. Furthermore, the experimental intervention will be a single-point cane with ergonomic handgrip (Mercur^®^), which is preferred by patients, requires less oxygen use at a given speed,[@bib0285], [@bib0290] and is relatively inexpensive (costs about US\$17).

This trial has some limitations. Participants and therapists cannot be blind, which is unpractical during the delivery of complex interventions. In addition, the experimental and control interventions consist of home exercises with no direct supervision, and, therefore, depend on the participant\'s motivation. Strategies to encourage participants to comply with the protocol, such as contracts, phone calls, and weekly visits, are planned.[@bib0250]

In conclusion, the results of this trial may result in an important advance in neurological rehabilitation. First, a low-cost, simple intervention may help improving walking of slow and intermediate walkers after stroke. Second, if walking is enhanced, the benefits may be carried over to participation, and individuals may experience greater free-living physical activity at home and in the community,[@bib0170], [@bib0295], [@bib0300] decreased disability and increased social interactions,[@bib0305], [@bib0310] and increased ability to engage in work and leisure activities, the ultimate goal for both patients and rehabilitation professionals.
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